Evidence map›Paper›PMID 37919330›Full record

ArticleScientific reports2023

High prevalence group testing in epidemiology with geometrically inspired algorithms.

Hannes Schenk, Yasemin Caf, Ludwig Knabl, Christoph Mayerhofer, Wolfgang Rauch

Abstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hannes SchenkUnit of Environmental Engineering, University of Innsbruck, Technikerstraße 13, 6020, Innsbruck, Austria.ORCID 0000-0003-4112-3915
Yasemin CafTyrolpath Obrist Brunhuber GmbH, Hauptplatz 4, 6511, Zams, Austria.
Ludwig KnablTyrolpath Obrist Brunhuber GmbH, Hauptplatz 4, 6511, Zams, Austria.ORCID 0000-0001-8280-8991
Christoph MayerhoferTyrolpath Obrist Brunhuber GmbH, Hauptplatz 4, 6511, Zams, Austria.ORCID 0000-0002-3512-069X
Wolfgang RauchUnit of Environmental Engineering, University of Innsbruck, Technikerstraße 13, 6020, Innsbruck, Austria. wolfgang.rauch@uibk.ac.at.ORCID 0000-0002-6462-2832

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Demand for mass surveillance during peak times of the SARS-CoV-2 pandemic caused high workload for clinical laboratories. Efficient and cost conserving testing designs by means of group testing can substantially reduce resources during possible future emergency situations. The novel hypercube algorithm proposed by Mutesa et al. 2021 published in Nature provides methodological proof of concept and points out the applicability to epidemiological testing. In this work, the algorithm is explored and expanded for settings with high group prevalence. Numerical studies investigate the limits of the adapted hypercube methodology, allowing to optimize pooling designs for specific requirements (i.e. number of samples and group prevalence). Hyperparameter optimization is performed to maximize test-reduction. Standard deviation is examined to investigate resilience and precision. Moreover, empirical validation was performed by elaborately pooling SARS-CoV-2 virus samples according to numerically optimized pooling designs. Laboratory experiments with SARS-CoV-2 sample groups, ranging from 50 to 200 items, characterized by group prevalence up to 10%, are successfully processed and analysed. Test-reductions from 50 to 72.5% were achieved in the experimental setups when compared to individual testing. Higher theoretical test-reduction is possible, depending on the number of samples and the group prevalence, indicated by simulation results.

Indexed as

Clinical Laboratory ServicesSARS-CoV-2AlgorithmsComputer SimulationPrevalence

Identifiers

PMID37919330
PMCPMC10622438

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.